Phase I clinical trial in Eastern Cooperative Oncology Group (ECOG) 0-1 patients with locally
advanced or metastatic NSCLC to evaluate safety and tolerability of the compound PBF-1129, an
Adenosine A2b receptor antagonist. The phase I dose escalation will be conducted 3+3 method.
Pharmacokinetic (PK) data will be also obtained.